Understanding Skin Cancer
Skin cancer includes melanoma and non-melanoma forms such as basal cell and squamous cell carcinoma. Outcomes are generally strong with early detection, and advanced therapies have transformed care for more advanced melanoma.
- Most Common Cancer Type
- Highly Treatable When Caught Early
- Immunotherapy & Targeted Therapy Available
- Most Common In
- Fair-skinned individuals with significant UV exposure
- Most Common Subtype
- Basal cell carcinoma (non-melanoma)
- Key Biomarker
- BRAF mutation status in melanoma
- Advanced Therapies
- Immune checkpoint inhibitors, BRAF/MEK inhibitors, TIL therapy
Condition Overview
Skin cancer develops when skin cells grow abnormally, most often as a result of cumulative ultraviolet (UV) radiation exposure. It is broadly divided into non-melanoma skin cancers (primarily basal cell and squamous cell carcinoma) and melanoma, which arises from pigment-producing melanocytes.
Non-melanoma skin cancers are far more common and rarely spread beyond the skin, making them highly treatable with local therapy. Melanoma is less common but has greater potential to spread to lymph nodes and distant organs, making early detection and accurate staging especially important.
Skin cancer is one of the most common cancers worldwide, and outcomes have improved substantially in recent years, particularly for advanced melanoma, due to the introduction of immune checkpoint inhibitors and targeted therapies.
Types and Subtypes
Skin cancer is grouped by the cell type from which it originates, which influences behavior and treatment approach.
Symptoms and Signs
Skin cancer often presents as a new or changing skin lesion, which is why regular self-examination is important.
Causes and Risk Factors
Cumulative sun exposure is the leading modifiable risk factor for skin cancer, though genetic and other factors also contribute.
Diagnosis and Investigations
Diagnosis begins with visual and dermoscopic examination, followed by tissue sampling to confirm the diagnosis and guide treatment.
Disease Staging and Risk Stratification
Melanoma is staged using the TNM system based on tumor thickness, ulceration, lymph node involvement, and distant spread; non-melanoma skin cancers are typically described by local risk features rather than formal TNM staging.
Standard Treatment Options
Treatment depends heavily on cancer type and stage, ranging from simple outpatient procedures for early non-melanoma skin cancer to systemic therapy for advanced melanoma.
Advanced and Emerging Treatment Options
Melanoma treatment has been transformed by immunotherapy and targeted therapy, with newer cellular therapies expanding options further.
Immunotherapy
Immune Checkpoint Inhibitors (e.g., anti-PD-1, anti-CTLA-4)
Activate the immune system to recognize and attack melanoma cells; standard of care for advanced and many higher-risk resected melanomas.
Targeted Therapy
BRAF/MEK Inhibitor Combinations
Block growth signaling in melanomas carrying BRAF mutations, used for both advanced disease and adjuvant treatment in eligible patients.
Cellular Therapy
Tumor-Infiltrating Lymphocyte (TIL) Therapy
Uses a patient's own immune cells extracted from the tumor, expanded in the lab, and reinfused; an option for advanced melanoma at specialized centers.
Oncolytic Virus Therapy
Intralesional Oncolytic Viral Therapy
Injected directly into accessible melanoma lesions to trigger local and systemic immune responses.
Targeted Therapy
Hedgehog Pathway Inhibitors
Used for advanced or metastatic basal cell carcinoma not amenable to surgery or radiation.
Biomarkers and Precision Medicine
Molecular testing increasingly guides treatment selection, particularly in melanoma.
When a Second Opinion May Be Important
Given the range of treatment approaches and rapid advances in melanoma therapy, specialist review can be valuable at several points in care.
Clinical Trials and Research
Prognosis and Key Outcome Factors
Prognosis in skin cancer varies widely by type and stage. Non-melanoma skin cancers are generally associated with very good outcomes when treated early, while melanoma prognosis depends heavily on thickness, ulceration, and the presence of spread.
Supportive Care and Living With Skin Cancer
Supportive care addresses both the physical and emotional aspects of living with skin cancer, particularly for those undergoing systemic therapy or facing ongoing surveillance.
How CancerFax Helps You Explore Treatment Options
CancerFax helps patients with melanoma and other skin cancers review pathology and biomarker reports, coordinate second opinions, and explore access to immunotherapy, targeted therapy, and cellular therapy options.
Get a free case reviewFrequently Asked Questions
Skin cancer is abnormal growth of skin cells, most often caused by UV exposure, and includes melanoma and non-melanoma types such as basal cell and squamous cell carcinoma.
A new or changing mole with irregular borders, multiple colors, asymmetry, or rapid growth are common early warning signs of melanoma.
Non-melanoma skin cancers such as basal cell carcinoma rarely spread but can cause local tissue damage if untreated, so prompt evaluation and treatment are still important.
BRAF testing identifies a mutation present in many melanomas that makes the tumor eligible for targeted BRAF/MEK inhibitor therapy.
Melanoma is staged using tumor thickness, ulceration status, lymph node involvement, and presence of distant metastasis under the TNM system.
Mohs micrographic surgery is a precise technique that removes thin layers of skin cancer one at a time, checking each under a microscope to spare as much healthy tissue as possible.
Advanced melanoma is commonly treated with immune checkpoint inhibitors, targeted BRAF/MEK inhibitors for eligible tumors, and in some cases TIL therapy or clinical trials.
Limiting UV exposure, using sunscreen, avoiding tanning beds, and having regular skin checks are key prevention strategies.
Recurrence risk depends on the type and stage of skin cancer; ongoing surveillance helps catch any recurrence early.
Yes. CancerFax helps patients review pathology and biomarker reports, coordinate second opinions with dermato-oncology specialists, and explore access to immunotherapy, targeted therapy, cellular therapy, and international treatment centers.
Diagnosed with Melanoma or Another Skin Cancer?
Send your medical reports for review or request a second opinion from a specialist.